Biotech Archives - Page 135 of 795

3 minute read

Biora Therapeutics Announces Initiation Of Phase 1 Clinical Study Of BT-600; First-In-Human Trial Of BT-600 Drug-Device Combination, Following Multiple Successful Device-only Human Studies

January 8, 9:19 AM

First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of BT-600, including concentrations in colon tissueSAN

BIOR

3 minute read

Viridian Therapeutics To Provide Key Updates On The Company’s Anti-Insulin-Like Growth Factor 1 Receptor Programs In Thyroid Eye Disease And Its Programs Targeting FcRn; VRDN-001 U.S. Annual Revenue ~$2B

By Benzinga Newsdesk

January 8, 9:17 AM

Thyroid Eye Disease Portfolio: VRDN-001 and VRDN-003Intravenous VRDN-001Viridian's lead product candidate, VRDN-001, is a monoclonal antibody that acts as a full antagonist of IGF-1R, a clinically and commercially

VRDN

2 minute read

ProSomnus Comments On Insurance Coverage Policy Update For Obstructive And Central Sleep Apnea

By Benzinga Newsdesk

January 8, 9:17 AM

ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of UnitedHealthcare's updated medical policy (#2024T0525NN) for Obstructive and

OSA

4 minute read

Vera Therapeutics To Host In-Person R&D Day In New York To Present Week 72 Data From Phase 2b ORIGIN Clinical Trial Of Atacicept In IgAN On January 25, 2024

By Benzinga Newsdesk

January 8, 9:16 AM

Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced it will host an

VERA

4 minute read

Xenon Pharmaceuticals Outlines Key Milestone Opportunities For 2024; Completion Of Patient Enrollment In XEN1101 Phase 3 X-TOLE2 Clinical Trial In Focal Onset Seizures Anticipated In Second Half Of 2024

By Benzinga Newsdesk

January 8, 9:15 AM

Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN1101 Phase 3 Program in Major Depressive Disorder Planned for Initiation in

XENE

2 minute read

AbbVie Says The Study’s Primary Endpoint Was An Achievement Of HiSCR 50 At Week 16, And The Secondary Endpoint Was Skin Pain NRS30 At Week 16 Among Subjects With Baseline NRS≥3

By Benzinga Newsdesk

January 8, 9:09 AM

AbbVie (NYSE:ABBV) today announced Phase 2 results showing adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg every other

ABBV

5 minute read

AbbVie Announces Lutikizumab Showed Results In A Phase 2 Trial Of Adults With Moderate To Severe Hidradenitis Suppurativa As Program Advances To Phase 3

By Benzinga Newsdesk

January 8, 9:07 AM

Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at

ABBV

2 minute read

Pasithea Therapeutics Announces Invention Of Crystalline Form Of PAS-004; Establishes Strengthened Intellectual Property Position

By Benzinga Newsdesk

January 8, 9:00 AM

-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio --SOUTH SAN FRANCISCO, Calif. and

KTTA

2 minute read

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

By Vandana Singh

January 8, 8:31 AM

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.

MRKR